You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,398,708

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,398,708 protect, and when does it expire?

Patent 10,398,708 protects IMVEXXY and is included in one NDA.

This patent has one hundred and sixty-two patent family members in twenty-one countries.

Summary for Patent: 10,398,708

Title:	Vaginal inserted estradiol pharmaceutical compositions and methods
Abstract:	In one aspect, compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises administering an estrogen to a subject having VVA by inserting a dosage form comprising a liquid pharmaceutical composition.
Inventor(s):	Mirkin; Sebastian (Boca Raton, FL), Amadio; Julia M. (Boca Raton, FL), Bernick; Brian A. (Boca Raton, FL)
Assignee:	TherapeuticsMD, Inc. (Boca Raton, FL)
Application Number:	15/893,542
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,398,708
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,398,708

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY	⤷ Sign Up
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA	⤷ Sign Up
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY	⤷ Sign Up
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,398,708

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2782584	⤷ Sign Up	301153	Netherlands	⤷ Sign Up
European Patent Office	2782584	⤷ Sign Up	2021C/558	Belgium	⤷ Sign Up
European Patent Office	2782584	⤷ Sign Up	122021000080	Germany	⤷ Sign Up
European Patent Office	2782584	⤷ Sign Up	LUC00245	Luxembourg	⤷ Sign Up
European Patent Office	2782584	⤷ Sign Up	132021000000197	Italy	⤷ Sign Up
European Patent Office	2782584	⤷ Sign Up	C202130068	Spain	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.